Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $73.00 Average PT from Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been given an average rating of “Moderate Buy” by the eleven analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $81.6667.

Several research analysts have recently weighed in on ARWR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday. HC Wainwright boosted their target price on shares of Arrowhead Pharmaceuticals from $85.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, January 21st. Morgan Stanley raised their price target on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 7th. Chardan Capital increased their price objective on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Finally, The Goldman Sachs Group raised their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 7th.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised several near‑term and FY2026/FY2027 EPS estimates, reiterated a “Buy” rating and a $100 price target — the firm says improving forecasts and program progress support upside. HC Wainwright Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals
• Positive Sentiment: B. Riley bumped its price target to $101 (from $61) and kept a “Buy” stance, implying significant upside from recent levels and signaling continued analyst conviction after Arrowhead’s program updates. B. Riley Raises ARWR Price Target to $101
• Positive Sentiment: Piper Sandler highlighted Arrowhead’s pipeline ahead of Phase III hypertriglyceridemia data and has increased its target (reported lift to $110), underscoring the potential for a clinical readout to re‑rate the stock if data are positive. Piper Sandler Highlights Arrowhead Pipeline
• Neutral Sentiment: Broader coverage pieces (InsiderMonkey/TheFly) recap the analyst upgrades and pipeline milestones — useful for context but largely reiterative of the broker notes above. InsiderMonkey: Piper Sandler Highlights Arrowhead
• Negative Sentiment: Despite the upgrades, shares are down today amid lower‑than‑average volume — likely profit‑taking following the recent run and continued investor caution given persistent GAAP losses and upcoming binary clinical readouts (which carry upside but also clinical risk).

Insider Activity

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 13,187 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $66.10, for a total transaction of $871,660.70. Following the completion of the sale, the chief executive officer directly owned 3,792,739 shares in the company, valued at $250,700,047.90. This trade represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adeoye Y. Olukotun sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $67.66, for a total transaction of $676,600.00. Following the completion of the transaction, the director owned 33,600 shares in the company, valued at approximately $2,273,376. This represents a 22.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 510,836 shares of company stock worth $33,603,060. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its position in Arrowhead Pharmaceuticals by 30.2% in the 1st quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock valued at $576,000 after acquiring an additional 10,496 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the first quarter valued at approximately $514,000. Goldman Sachs Group Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 34.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after purchasing an additional 447,456 shares during the period. Empowered Funds LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 6.9% in the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 979 shares in the last quarter. Finally, Focus Partners Wealth increased its stake in Arrowhead Pharmaceuticals by 1,339.5% during the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock worth $207,000 after buying an additional 15,123 shares during the period. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $67.05 on Wednesday. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $76.76. The stock has a market cap of $9.11 billion, a PE ratio of -838.02 and a beta of 1.21. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The stock has a 50 day moving average price of $62.41 and a 200 day moving average price of $40.26.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.